Pressemeddelelse

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Lund, November 3, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data of tasquinimod in combination with T cell activation has been accepted for presentation at the 67th American Society of Hematology Annual Meeting in Orlando, December 6-9, 2025 (ASH 2025). The abstract demonstrating additive efficacy of tasquinimod combined with a T cell enhancer in experimental models of multiple myeloma, will be presented as a poster. The accepted abstracts for ASH 2025 were published today, November 3, 2025.

The abstract, entitled IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma, will be presented by Hatice Satilmis, Translational Oncology Research Center, Lab of Hematology and Immunology, Vrije Universiteit Brussel, Belgium. The abstract is a result of the collaboration between Active Biotech and Ass Prof Dr Kim de Veirman’s research group at Vrije Universiteit Brussel, Belgium, and aims to support the clinical development of tasquinimod in hematological malignancies.

Data to be presented demonstrate the enhancement of the anti-tumor effect of T cell activation when combined with tasquinimod. The tumor cells were further decreased, and immune cells such as T and NK cells became more active, leading to an increased therapeutic effect.

“The immune suppressive bone marrow limits the effect of immunotherapy such as T cell activation in multiple myeloma. Data to be presented suggest increased therapeutic efficacy of a T cell activator when combined with tasquinimod in a model of multiple myeloma. This highlights tasquinimod's ability to restore antitumor immunity within the tumor microenvironment and is also relevant for other hematological cancers,” said Marie Törngren, VP R&D at Active Biotech.

Information on the presentation:
Publication Number: 5696 IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM (local time)
Location: Orlando Convention Center, West Halls B3-B4

The abstracts will be available online on ASH’s website from 09:00 Eastern time (15:00 CET) on November 3, 2025.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. A clinical Phase Ib/IIa study in multiple myeloma has been concluded. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

About tasquinimod

Tasquinimod is an orally active small molecule immunomodulator with a novel mode of action, blocking tumor supporting pathways in the bone marrow microenvironment. Tasquinimod is being developed as a new immunomodulatory treatment for hematological malignances. Tasquinimod has previously been studied as an anti-cancer agent in patients with solid cancers, including a phase III randomized trial in patients with metastatic prostate cancer. The tolerability of tasquinimod is well-characterized based on these previous experiences. Tasquinimod has demonstrated a clear therapeutic potential in preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy. A clinical Phase Ib/IIa study with tasquinimod in relapsed and refractory multiple myeloma has been concluded. Tasquinimod ameliorates disease development in preclinical models for myelofibrosis. Clinical proof-of-concept studies have been initiated in Europe and in the US.